Catalyst Pharmaceuticals (CPRX) Competitors

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability, community ranking and valuation.

Does the media refer more to CPRX or ASND?

In the previous week, Ascendis Pharma A/S had 4 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 14 mentions for Ascendis Pharma A/S and 10 mentions for Catalyst Pharmaceuticals. Ascendis Pharma A/S's average media sentiment score of 0.96 beat Catalyst Pharmaceuticals' score of 0.83 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Catalyst Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher earnings & valuation, CPRX or ASND?

Catalyst Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$534.65M	5.80	$71.41M	$1.57	16.18
Ascendis Pharma A/S	$368.70M	28.45	-$409.12M	-$6.28	-27.34

Do analysts rate CPRX or ASND?

Catalyst Pharmaceuticals currently has a consensus price target of $32.83, indicating a potential upside of 29.21%. Ascendis Pharma A/S has a consensus price target of $217.73, indicating a potential upside of 26.80%. Given Catalyst Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Catalyst Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25
Ascendis Pharma A/S	0 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community prefer CPRX or ASND?

Catalyst Pharmaceuticals received 49 more outperform votes than Ascendis Pharma A/S when rated by MarketBeat users. Likewise, 75.15% of users gave Catalyst Pharmaceuticals an outperform vote while only 67.26% of users gave Ascendis Pharma A/S an outperform vote.

Company	Underperform	Outperform
Catalyst Pharmaceuticals	Outperform Votes 505 75.15%	Underperform Votes 167 24.85%
Ascendis Pharma A/S	Outperform Votes 456 67.26%	Underperform Votes 222 32.74%

Do institutionals & insiders have more ownership in CPRX or ASND?

79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Is CPRX or ASND more profitable?

Catalyst Pharmaceuticals has a net margin of 31.01% compared to Ascendis Pharma A/S's net margin of -104.54%. Catalyst Pharmaceuticals' return on equity of 40.79% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	31.01%	40.79%	34.87%
Ascendis Pharma A/S	-104.54%	N/A	-39.23%

Which has more risk and volatility, CPRX or ASND?

Catalyst Pharmaceuticals has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500.

Summary

Catalyst Pharmaceuticals beats Ascendis Pharma A/S on 14 of the 19 factors compared between the two stocks.